

Financial news for DSCI dated on 2017-02-23: Integra LifeSciences Reports Acceptance of Shares Tendered Into Offer for Derma Sciences

Financial news for DSCI dated on 2017-01-11: Derma Sciences Buys MEDIHONEY From Comvita Ltd For \$13.25M Cash Upfront, Add'l \$5M Potential Payable

Financial news for DSCI dated on 2017-01-11: Mid-Afternoon Market Update: Derma Sciences Climbs On Acquisition News; Novadaq Shares Plunge

Financial news for DSCI dated on 2017-01-11: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for DSCI dated on 2017-01-11: Mid-Day Market Update: Crude Oil Up 2.5%; Ethan Allen Shares Drop On Weak Forecast

Financial news for DSCI dated on 2017-01-11: Mid-Morning Market Update: Markets Mostly Higher; SUPERVALU Earnings Miss Views

Financial news for DSCI dated on 2017-01-11: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for DSCI dated on 2017-01-11: Integra Lifesciences to Acquire Derma Sciences for \$7.00/Share in Cash

Financial news for DSCI dated on 2016-11-10: Derma Sciences Reports Q3 EPS \$(0.05) vs. Est. \$(0.04), Rev. \$21.8M vs. Est. \$23.9M

Financial news for DSCI dated on 2016-08-25: Derma Sciences Receives Reimbursement Coding for New MEDIHONEY Hydrogel Dressings

Financial news for DSCI dated on 2016-08-24: Derma Sciences' AMNIOEXCEL Now Eligible for Reimbursement by Medicare Administrative Contractor NGS

Financial news for DSCI dated on 2016-08-09: Derma Sciences Reports Q2 EPS from Continuing Operations \$0.08 vs \$(0.19) in Same Qtr. Last Year, Sales \$22.2M vs \$22.4M Est.

Financial news for DSCI dated on 2016-07-28: Derma Sciences Reports Deal to Buy BioD for Immediate Value of \$21.3M, Potential Value of \$77.8M

Financial news for DSCI dated on 2016-07-27: Derma Sciences Announces Sale of First Aid Products Unit for ~\$12.2M

Financial news for DSCI dated on 2016-05-11: Derma Sciences Reports Q1 EPS \$(0.07) vs \$(0.13) Est., Sales \$20.2M vs \$20.6M Est.

Financial news for DSCI dated on 2016-04-27: Derma Sciences Announces AMNIOEXCEL Is Now Eligible for Reimbursement by Medicare Administrative Contractor CGS

Financial news for DSCI dated on 2016-03-16: Derma Sciences Affirms FY16 Outlook: Sales ~\$89.1M vs \$89M Est.

Financial news for DSCI dated on 2016-03-16: Derma Sciences Reports Q4 EPS \$(0.36) vs \$(0.39) Est., Sales \$20.25M vs \$20.21M Est.

Financial news for DSCI dated on 2016-03-16: Earnings Scheduled For March 16, 2016

Financial news for DSCI dated on 2016-01-07: Derma Sciences Sees FY16 Sales \$89.1M vs. Est. \$97.04M

Financial news for DSCI dated on 2016-01-07: Derma Sciences Reports Prelim. Q4 Sales \$20.2M vs. Est. \$23.78M, FY15 Rev. \$84.5M vs. Est. \$88.07M

Financial news for DSCI dated on 2015-12-21: Derma Sciences CEO Edward Quilty To Leave Company, Names Stephen Willis Interim Executive Chairman

Financial news for DSCI dated on 2015-11-12: Morning Market Losers

Financial news for DSCI dated on 2015-11-12: Shares of Derma Sciences to Resume Trade at 8 a.m. EST

Financial news for DSCI dated on 2015-11-12: UPDATE: Derma Sciences Announces Results of Futility Analyses for Phase 3 Clinical Trials of Aclerastide in Diabetic Foot Ulcer Healing Press Release

Financial news for DSCI dated on 2015-11-12: Derma Sciences Reports Results of Futility Analyses for Phase 3 Clinical Trials of Aclerastide in Diabetic Foot Ulcer Healing, Trial Stopped For Early For Futility

Financial news for DSCI dated on 2015-11-12: BZ NOTE: Derma Sciences To Discuss Data

Monitoring Committee Pre-Specified Interim Analysis Of Acclerastide Ph 3 Trials At 7:30am ET, Shares Halted News Pending

Financial news for DSCI dated on 2015-11-12: Derma Sciences Shares Halted News Pending

Financial news for DSCI dated on 2015-11-09: Derma Sciences Reports Q3 EPS \$(0.35) vs \$(0.43) Est., Sales \$22.2M vs \$22.3M Est.; Sees FY15 Sales ~\$88.1M vs \$88.1M Est.

Financial news for DSCI dated on 2015-08-10: Derma Sciences Reports Q2 Loss of \$0.36/Share vs Loss of \$0.42/Share Est., Sales \$22.6M vs \$21.7M Est.

Financial news for DSCI dated on 2015-06-18: Derma Sciences Announces Closing of Non-Clinical Acclerastide Toxicology Program

Financial news for DSCI dated on 2015-06-17: Derma Sciences Announces Medicare Coverage Reinstated For MEDIHONEY Products with Reimbursable Codes by Centers for Medicare & Medicaid Services

Financial news for DSCI dated on 2015-05-19: Derma Sciences Updates Acclerastide Phase 3 Trials

Financial news for DSCI dated on 2015-05-11: Derma Sciences Q1 EPS -\$0.42 vs -\$0.48 est

Financial news for DSCI dated on 2015-03-18: 13D Filing Shows Derma Sciences Holder Broadfin Reports 8.3% Stake, Up From 7.22% On Dec 31 2014

Financial news for DSCI dated on 2015-03-12: Derma Sciences Reports Q4 GAAP Loss of \$0.37/Share, Sales \$22.9M; Reaffirms FY Sales Outlook

Financial news for DSCI dated on 2015-03-12: Earnings Scheduled For March 12, 2015

Financial news for DSCI dated on 2015-03-09: Derma Sciences Appoints John Caminis, M.D. Chief Medical Officer

Financial news for DSCI dated on 2015-01-26: Piper Jaffray Downgrades Derma Sciences to Neutral, Lowers PT to \$9.00

Financial news for DSCI dated on 2015-01-08: Derma Sciences Sees FY2014 Sales \$88.10M vs \$84.32M Est

Financial news for DSCI dated on 2015-01-08: Derma Sciences Reports Prelim. Q4 Sales \$22.90M-23.40M

Financial news for DSCI dated on 2014-11-10: Derma Sciences, Inc. Reports Q3 EPS of \$(0.45) vs \$(0.43) Est; Revenue of \$20.17M vs \$21.93M Est

Financial news for DSCI dated on 2014-11-07: Derma Sciences, Inc. Reports Q3 EPS of \$(0.45) Which May Not Compare \$(0.43) Est; Revenue of \$20.20M Which May Not Compare \$21.93M Est

Financial news for DSCI dated on 2014-08-07: Derma Sciences, Inc. Reports Q2 EPS of \$(0.34) vs \$(0.46) Est; Revenue of \$20.92M vs \$21.47M Est

Financial news for DSCI dated on 2014-05-08: Derma Sciences, Inc. Reports Q1 EPS of \$(0.46) vs \$(0.32) Est; Revenue of \$19.80M vs \$20.55M Est

Financial news for DSCI dated on 2014-03-14: Derma Sciences, Inc. Reports Q4 EPS of \$(0.31) vs \$(0.36) Est; Revenue of \$20.70M vs \$21.26M Est; Reaffirms Outlook

Financial news for DSCI dated on 2014-03-14: Earnings Scheduled For March 14, 2014

Financial news for DSCI dated on 2014-01-29: Derma Sciences Closes Offering of 7.5M Shares at \$11.50/Share for Total Net Proceeds \$80.7M

Financial news for DSCI dated on 2014-01-24: Derma Sciences Prices 6.5M Share Offering at \$11.50/Share

Financial news for DSCI dated on 2014-01-23: Derma Sciences Announces Commencement of Public Offering of Common Stock

Financial news for DSCI dated on 2014-01-16: Derma Sciences, Inc. Sees FY2014 Sales \$92.0M vs \$94.60M Est

Financial news for DSCI dated on 2014-01-16: Derma Sciences, Inc. Sees FY2013 Sales \$79.70M vs \$82.40M Est

Financial news for DSCI dated on 2014-01-14: Derma Sciences Announces Licensing Pact

with BioD, Includes Upfront Cash Payments, Royalties

Financial news for DSCI dated on 2014-01-14: Derma Sciences Licenses Rights to Two Human Placental-Derived Tissue Products from BioD

Financial news for DSCI dated on 2013-12-19: Derma Sciences Files \$75M Mixed Securities Shelf

Financial news for DSCI dated on 2013-11-13: Derma Sciences, Inc. Reports Q3 EPS of \$(0.29) vs \$(0.45) Est; Revenue of \$22.08M vs \$19.95M Est

Financial news for DSCI dated on 2013-11-13: Earnings Scheduled For November 13, 2013

Financial news for DSCI dated on 2013-08-12: Derma Sciences, Inc. Reports Q2 EPS of \$(0.43) vs \$(0.45) Est; Revenue of \$18.15M vs \$19.95M Est

Financial news for DSCI dated on 2013-08-12: Derma Sciences Ships First MEDIHONEY over-the-counter Product to Leading U.S. Pharmacy Chain

Financial news for DSCI dated on 2013-08-12: Earnings Scheduled For August 12, 2013

Financial news for DSCI dated on 2013-06-12: Derma Sciences Reports Results from DSC127 Pharmacokinetic Study

Financial news for DSCI dated on 2013-05-16: Derma Sciences, Inc. Reports Q1 EPS of \$(0.38) vs \$(0.37) Est; Revenue of \$18.80M vs \$19.0M Est

Financial news for DSCI dated on 2013-05-16: Earnings Scheduled For May 16, 2013

Financial news for DSCI dated on 2013-04-25: Derma Sciences Begins Screening Patients in Second Phase 3 Trial with DSC127 for Healing Diabetic Foot Ulcers

Financial news for DSCI dated on 2013-04-01: Derma Sciences Surges on Successful Earnings

Financial news for DSCI dated on 2013-04-01: Derma Sciences, Inc. Reports Q4 EPS of \$(0.27) vs \$(0.31) Est; Revenue of \$20.10M vs \$19.73M Est

Financial news for DSCI dated on 2013-04-01: Earnings Scheduled For April 1, 2013

Financial news for DSCI dated on 2013-02-06: Derma Sciences Begins Enrollment in DSC127 Phase 3 Trial

Financial news for DSCI dated on 2012-12-11: Derma Sciences Closes \$36.4M Offering of Stock, Sees Net Proceeds of \$33.8M After Items

Financial news for DSCI dated on 2012-12-06: Derma Sciences Prices Public Offering of 3.06M Share at \$10.34/Share

Financial news for DSCI dated on 2012-12-06: Derma Sciences Registers Added \$6.1M to Securities Shelf

Financial news for DSCI dated on 2012-11-13: UPDATE: Canaccord Maintains Buy Derma Sciences based on Solid Q3, Lowers PT

Financial news for DSCI dated on 2012-11-12: Canaccord Maintains Derma Sciences New at Buy, Lowers PT from \$18 to \$16.50

Financial news for DSCI dated on 2012-11-12: Derma Sciences New Reports Q3 EPS \$-0.24 vs \$-0.37 Est; Revenues \$19.6M vs \$19.00M Est

Financial news for DSCI dated on 2012-11-12: Earnings Scheduled For November 12, 2012

Financial news for DSCI dated on 2012-09-06: Derma Sciences Launches Medihoney Product in US

Financial news for DSCI dated on 2012-08-15: UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Derma Sciences

Financial news for DSCI dated on 2012-08-15: Canaccord Genuity Reiterates Buy Rating, \$18 PT on Derma Sciences

Financial news for DSCI dated on 2012-08-15: Piper Jaffray Maintains Derma Sciences New at Overweight, Raises PT from \$13 to \$16

Financial news for DSCI dated on 2012-07-23: Derma Sciences Announces Issuance of Two New U.S. Patents For DSC127

Financial news for DSCI dated on 2012-07-13: Derma Sciences Acquires Global Long-Term

Exclusive Rights to NIMBUS Technology from Quick-Med Technologies; \$1.3M Upfront Payment

Financial news for DSCI dated on 2012-05-15: Earnings Scheduled For May 15

Financial news for DSCI dated on 2012-04-13: UPDATE: Piper Jaffray Initiates Overweight, \$13 PT on Derma Sciences

Financial news for DSCI dated on 2012-04-13: Piper Jaffray Initiates Coverage on Derma Sciences New at Overweight, Announces PT of \$13

Financial news for DSCI dated on 2012-04-03: UPDATE: Oppenheimer Cuts Target to \$19 on Derma Sciences

Financial news for DSCI dated on 2012-04-03: Oppenheimer Maintains Derma Sciences New at Outperform, Lowers PT from \$21 to \$19

Financial news for DSCI dated on 2012-04-02: Derma Sciences Announces Pricing of Underwritten Registered Direct Offering of Common Stock, 2.125M Shares at \$9.25/Share

Financial news for DSCI dated on 2012-03-30: Canaccord Maintains Derma Sciences at Buy, Raises PT from \$19 to \$20

Financial news for DSCI dated on 2012-03-29: Market Update

Financial news for DSCI dated on 2012-03-29: Derma Sciences to Acquire MedEfficiency; Expands Proprietary Advanced Wound Care Product Offering with High-Growth, Market-Leading, Gold-Standard Treatment for Diabetic Foot Ulcers

Financial news for DSCI dated on 2012-03-29: Earnings Scheduled For March 29

Financial news for DSCI dated on 2012-03-06: Derma Says FDA Agrees Program to Date Supports Starting Phase 3 -Bloomberg

Financial news for DSCI dated on 2012-03-06: Derma Sciences Meeting with FDA Supports Initiation of Phase 3 Studies with DSC127 in Diabetic Foot Ulcers

Financial news for DSCI dated on 2011-08-08: Derma Sciences Achieves Key MEDIHONEY Sales Milestone

Financial news for DSCI dated on 2011-08-01: Derma Sciences Receives FDA Clearance for MEDIHONEY Hydrogel

Financial news for DSCI dated on 2011-07-06: UPDATE: Oppenheimer Initiates Derma Sciences at Outperform

Financial news for DSCI dated on 2011-07-06: Oppenheimer Initiates Derma Sciences At Outperform, \$21 PT

Financial news for DSCI dated on 2011-06-20: Derma Sciences Raises \$29 Million in Private Placement Financing

Financial news for DSCI dated on 2011-05-24: Derma Sciences to Hold Conference Call Tomorrow, May 25 to Discuss 24-Week Data from Phase 2 DSC127 Trial in Diabetic Foot Ulcer

Financial news for DSCI dated on 2011-03-30: Derma Sciences Reports Q4 Loss of \$0.05 per share

Financial news for DSCI dated on 2011-03-30: Derma Sciences Reports Q4 EPS of \$(0.05) vs. \$(0.07)

Financial news for DSCI dated on 2011-03-30: Earnings Scheduled For March 30 (AYI, FDO, SIG, ES, MOS, UNF, AMCF, DIET, CWS, DSCI, DRYS, INV, DRJ)

Financial news for DSCI dated on 2011-02-28: Derma Sciences Receives FDA Clearance for MEDIHONEY Gel